| New horizons for precision medicine in biliary tract cancers JW Valle, A Lamarca, L Goyal, J Barriuso, AX Zhu Cancer discovery 7 (9), 943-962, 2017 | 520* | 2017 |
| Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms M Heetfeld, CN Chougnet, IH Olsen, A Rinke, I Borbath, G Crespo, ... Endocrine-related cancer 22 (4), 657-664, 2015 | 403 | 2015 |
| Molecular targeted therapies: ready for “prime time” in biliary tract cancer A Lamarca, J Barriuso, MG McNamara, JW Valle Journal of hepatology 73 (1), 170-185, 2020 | 267 | 2020 |
| The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients S Leskelä, LJ Leandro-García, M Mendiola, J Barriuso, L Inglada-Pérez, ... Endocrine-related cancer 18 (1), 85-95, 2011 | 237 | 2011 |
| Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies TA Yap, D Olmos, AT Brunetto, N Tunariu, J Barriuso, R Riisnaes, L Pope, ... Journal of Clinical Oncology 29 (10), 1271-1279, 2011 | 222 | 2011 |
| Prospective validation of a prognostic score to improve patient selection for oncology phase I trials HT Arkenau, J Barriuso, D Olmos, JE Ang, J de Bono, I Judson, S Kaye J Clin Oncol 27 (16), 2692-2696, 2009 | 203 | 2009 |
| KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis P Cejas, M Lopez-Gomez, C Aguayo, R Madero, J de Castro Carpeno, ... PloS one 4 (12), e8199, 2009 | 196 | 2009 |
| Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies D Olmos, D Barker, R Sharma, AT Brunetto, TA Yap, AB Taegtmeyer, ... Clinical cancer research 17 (10), 3420-3430, 2011 | 188 | 2011 |
| A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma DA Reardon, MD Groves, PY Wen, L Nabors, T Mikkelsen, S Rosenfeld, ... Clinical Cancer Research 19 (4), 900-908, 2013 | 123 | 2013 |
| Zebrafish: a new companion for translational research in oncology J Barriuso, R Nagaraju, A Hurlstone Clinical Cancer Research 21 (5), 969-975, 2015 | 117 | 2015 |
| A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric … YK Kang, SY Rha, P Tassone, J Barriuso, R Yu, T Szado, A Garg, ... British journal of cancer 111 (4), 660-666, 2014 | 111 | 2014 |
| Cardiac toxicity: old and new issues in anti-cancer drugs M Sereno, A Brunello, A Chiappori, J Barriuso, E Casado, C Belda, ... Clinical and Translational Oncology 10, 35-46, 2008 | 103 | 2008 |
| Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? S Postel-Vinay, HT Arkenau, D Olmos, J Ang, J Barriuso, S Ashley, ... British journal of cancer 100 (9), 1373-1378, 2009 | 102 | 2009 |
| Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing Z Miskolczi, MP Smith, EJ Rowling, J Ferguson, J Barriuso, C Wellbrock Oncogene 37 (23), 3166-3182, 2018 | 100 | 2018 |
| 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis A Lamarca, J Barriuso, A Chander, MG McNamara, RA Hubner, D ÓReilly, ... Journal of hepatology 71 (1), 115-129, 2019 | 97 | 2019 |
| Biomarker concordance between primary colorectal cancer and its metastases DS Bhullar, J Barriuso, S Mullamitha, MP Saunders, ST O'Dwyer, O Aziz EBioMedicine 40, 363-374, 2019 | 96 | 2019 |
| Angiogenesis and ovarian cancer C Gómez-Raposo, M Mendiola, J Barriuso, E Casado, D Hardisson, ... Clinical and Translational Oncology 11, 564-571, 2009 | 93 | 2009 |
| Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study M Martin-Richard, R Gallego, C Pericay, JG Foncillas, B Queralt, ... Investigational new drugs 31, 1573-1579, 2013 | 82 | 2013 |
| A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond C Gomez-Martín, F Lopez-Rios, J Aparicio, J Barriuso, ... Cancer letters 351 (1), 30-40, 2014 | 80 | 2014 |
| Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy V Moreno García, P Cejas, M Blanco Codesido, J Feliu Batlle, ... International journal of colorectal disease 24, 741-748, 2009 | 66 | 2009 |
